Skip to main content
. Author manuscript; available in PMC: 2016 Nov 11.
Published in final edited form as: Expert Rev Mol Diagn. 2015 Nov 11;15(12):1631–1644. doi: 10.1586/14737159.2015.1110021

Table 5.

Overview of active clinical trials with cfDNA as their primary or secondary objective

Cancer type Clinical trials with cfDNA as primary or secondary objective [ClinicalTrials.gov Identifier]
Assesment of prognosis Prediction and monitoring of response to therapy Detection of disease recurrence Detection of resistance to therapy
Breast cancer NCT00899548, NCT02306096 NCT01617915, NCT00899548, NCT02109913, NCT01160211, NCT02318901 NCT01617915, NCT02318901 NCT01884285
Lung cancer NCT02245100 NCT02169349, NCT01930474, NCT02186236, NCT01884285, NCT02281214 NCT02169349 NCT02169349, NCT01930474, NCT01884285, NCT02281214, NCT00997334
Colorectal cancer NCT01198743 NCT01983098, NCT01212510, NCT01943786 NCT01983098, NCT01943786, NCT01198743
Melanoma NCT02251314, NCT02171286, NCT02071940 NCT02251314, NCT02133222, NCT02071940
Pancreatic cancer NCT02072616, NCT02331251 NCT02331251 NCT02331251
Hepatocellular carcinoma NCT02036216 NCT02036216 NCT02036216
Gastrointestinal stromal tumor NCT01462994 NCT02331914 NCT02331914
Lymphoma NCT02339805 NCT02339805
Prostate cancer NCT01884285 NCT01884285
Thyroid cancer NCT01723202